Filing summary
Entity and period: The supplied metadata names IMMUNIC, INC., but this 10-K identifies the registrant as Vital Therapies, Inc. It reports on the fiscal year ended December 31, 2016, and was filed March 7, 2017. The company was a clinical-stage biotherapeutic developer, with ELAD as its sole product candidate and no revenue from planned principal operations.
Business context and outlook
Vital Therapies was developing ELAD, an extracorporeal treatment using human liver-derived cells, primarily for severe acute alcoholic hepatitis (sAAH). Its VTL-308 Phase 3 trial was based on subgroup analyses of the earlier VTI-208 trial, which failed to meet its primary and secondary endpoints in the overall population. As of February 28, 2017, VTL-308 had enrolled 53 subjects and had 39 sites open; the company planned to enroll at least 150 subjects and observe at least 55 events, and expected top-line results around mid-2018. The company cautioned that trial success was uncertain and one successful trial might not suffice for regulatory approval.
Financial performance and liquidity
| Metric | FY 2016 | FY 2015 | Change / context |
|---|---|---|---|
| Revenue | None reported | None reported | No product revenue to date |
| Research and development expense | $30.0 million | $39.8 million | Down 24%, mainly due to lower clinical-trial and related costs |
| General and administrative expense | $11.2 million | $12.3 million | Down 9% |
| Total operating expenses | $41.3 million | $52.1 million | Down 21% |
| Net loss | $41.0 million | $52.0 million | Loss narrowed by about $11.1 million |
| Net loss per share | $1.31 | $2.07 | Basic and diluted |
| Operating cash used | $35.8 million | $50.0 million | Cash burn declined |
| Cash and cash equivalents | $60.0 million | $83.4 million | Down $23.4 million; no restricted cash at year-end 2016 |
| Working capital | $56.0 million | $78.4 million | Down $22.5 million |
| Total assets / stockholders’ equity | $64.0 million / $58.4 million | $89.1 million / $82.3 million | Lower largely as cash was spent on operations |
Cash used in investing activities was $0.02 million in 2016; financing provided $12.4 million net, primarily from equity issuance. No material interest-bearing debt is identified in the supplied balance sheet; total liabilities were approximately $5.6 million, including $0.1 million of long-term liabilities. Gross margin is not applicable because the company had no product sales. Management estimated year-end cash would fund operations through the first quarter of 2018, assuming its plans; it expected to need additional funds before VTL-308 top-line results.
Material changes, clinical evidence, and notable items
- VTI-208’s overall-population survival result remained negative in extended follow-up (203 subjects; p=0.868; hazard ratio 1.029). In a subgroup with MELD scores below 28, survival favored ELAD but did not reach conventional statistical significance (p=0.076). Other subgroup results favored control in more severe patients.
- A narrower, post-hoc VTI-208 subgroup matching key VTL-308 criteria showed a favorable result (60 subjects; p=0.019; hazard ratio 0.391; day-91 survival 93.1% versus 61.3%). This is exploratory retrospective evidence, not proof that the ongoing trial will succeed.
- The company discontinued VTI-210 and VTI-212 in 2015, reduced its workforce, and postponed most BLA-preparation work. It expected R&D spending to increase in 2017 as VTL-308 enrollment and possible BLA preparation advanced.
- Additional financing is a key contingency. If unable to raise funds, management said it expected to reduce spending and focus available resources on obtaining VTL-308 data. Equity financing could dilute shareholders; debt or collaboration terms could constrain operations or require rights to be relinquished.
- Commercialization, pricing, and reimbursement remain uncertain. A prior study suggested a U.S. price range of $150,000–$275,000 per treatment, but the company said this was not established and could prove unattainable.
- Key risks include trial failure or delay, potential need for another pivotal trial, treatment-related bleeding or hemolysis and other safety risks, narrow eligibility criteria, dependence on single-source suppliers, manufacturing scale-up, and regulatory approval. U.S. and European orphan designations do not guarantee approval.
- The company reported no current litigation it believed would materially affect it. Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2016; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for Vital Therapies, Inc. (NASDAQ: VTL), not IMMUNIC, INC.
- Track VTL-308 enrollment, event count, trial conduct, and whether the planned mid-2018 data timing changes.
- Assess the prespecified trial results separately from the failed VTI-208 overall result and its exploratory subgroup findings.
- Verify cash runway, subsequent equity issuance, dilution, and the timing and terms of any additional financing.
- Monitor whether regulators require confirmatory trials and whether manufacturing, safety, pricing, or reimbursement issues affect approval prospects.